UBS Group
BCTXW

UBS Group’s BriaCell Therapeutics Corp Warrant BCTXW Stock Holding History

UBS Group’s Portfolio BCTXW Stock Details BCTXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-314
Closed -$24 – 10340
2025
Q2 		$24 Sell
314
-2,375
-88% -$215 ﹤0.01% 10110
2025
Q1 		$274 Sell
2,689
-3,724
-58% -$516 ﹤0.01% 9855
2024
Q4 		$1.85K Sell
6,413
-22,645
-78% -$7.67K ﹤0.01% 9155
2024
Q3 		$11.9K Buy
29,058
+19,035
+190% +$4.17K ﹤0.01% 7657
2024
Q2 		$2.7K Buy
+10,023
New +$7.21K ﹤0.01% 8312
2023
Q4 		– Sell
-142
Closed -$351 – 9309
2023
Q3 		$351 Buy
+142
New +$354 ﹤0.01% 8560
2023
Q1 		– Sell
-1,441
Closed -$2.97K – 9604
2022
Q4 		$2.97K Sell
1,441
-1,492
-51% -$3.48K ﹤0.01% 9593
2022
Q3 		$8K Sell
2,933
-2,140
-42% -$6.39K ﹤0.01% 8690
2022
Q2 		$13K Buy
5,073
+3,936
+346% +$12.6K ﹤0.01% 7491
2022
Q1 		$6K Buy
+1,137
New +$4.53K ﹤0.01% 8949
2021
Q4 		– Sell
-2,082
Closed -$10K – 10247
2021
Q3 		$10K Buy
+2,082
New +$5.11K ﹤0.01% 7984

Other funds holding BCTXW

RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

UBS Group's BCTXW Position: Q3 2025 in Review

UBS Group sold out of BriaCell Therapeutics Corp Warrant (BCTXW) in Q3 2025, closing a stake of 314 shares — an estimated $24 sold.

UBS Group first reported a position in BCTXW in Q3 2021 and held it in 11 quarters. The position peaked at $13K in Q2 2022. 3 funds tracked by Wall St. Rank hold BCTXW as of Q3 2025.

  • UBS Group reported no remaining BriaCell Therapeutics Corp Warrant position as of Q3 2025 after selling out during the quarter.
  • UBS Group sold 314 BriaCell Therapeutics Corp Warrant shares in Q3 2025, an estimated $24.
  • UBS Group first reported a position in BriaCell Therapeutics Corp Warrant in Q3 2021 and held it in 11 quarters.
  • UBS Group's BriaCell Therapeutics Corp Warrant position peaked at $13K in Q2 2022.
  • 3 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.